Supplementary Figures 1–20 from Lymph Node–Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors

Abstract

<p>Supplementary Fig. S1: Design of a lymph node-targeted TCR-T cell therapy vaccine combination. Supplementary Fig. S2: Representative flowcytometric gating strategy. Supplementary Fig. S3: TCR-T therapy in irradiation pre-conditioned hosts does not improve activity against established B16F10 tumors. Supplementary Fig. S4: AMP-vaccination enhances TCR-T cell therapy and eradicates established B16F10 solid tumors. Supplementary Fig. S5: Vaccination alone is not effective to treat established B16F10 solid tumors. Supplementary Fig. S6: AMP-vaccination enhances TCR-T cell therapy against B16F10 solid tumors at multiple TCR-T dose levels. Supplementary Fig. S7: AMP-vaccination enhances TCR-T cell therapy and eradicates established solid tumors. Supplementary Fig. S8: Exposure to lymph nodes from AMP-vaccinated mice enhances TCR-T cell cytokine production ex vivo. Supplementary Fig. S9: Exposure to lymph nodes from AMP-vaccinated mice enhance antigen-specific naïve TCR-T cell cytokine production ex vivo. Supplementary Fig. S10: Gene ontology pathway classification for Nanostring analysis. Supplementary Fig. S11: AMP-vaccination induces differential mRNA levels across a broad range of transcripts present in lymph node and tumor. Supplementary Fig. S12: Tumor infiltrating TCR-T cells induced by AMP-vaccination do not exhibit exhausted phenotype. Supplementary Fig. S13: AMP-vaccine combination with TCR-T results in tumor-specific endogenous T cell responses in lymph nodes which correlate to tumor infiltrating responses. Supplementary Fig. S14: Depletion of TCR-T cells from long-term survivors. Supplementary Fig. S15: Schematic of vaccination protocol with fluorescently labelled components. Supplementary Fig. S16: AMP-vaccination induces DC activation within lymph nodes of HLA A*11:01 transgenic mice. Supplementary Fig. S17: NY-ESO-1-specific human TCR-T cells are specifically activated by AMP-peptide pulsed autologous DCs in vitro. Supplementary Fig. S18: mKRAS- and HPV16 E7-specific human TCR-T cells are specifically activated by AMP-peptide-pulsed autologous DCs in vitro. Supplementary Fig. S19: mKRAS-specific human TCR-T cells are specifically activated in vitro by autologous DCs pulsed with AMP-peptides incubated in mock in vivo conditions. Supplementary Fig. S20: mKRAS-specific human TCR-T cells co-cultured with AMP-peptide-pulsed autologous DCs in vitro enhance in vivo anti-tumor efficacy.</p>